# Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT04646356** · PHASE2 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 10 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Epistaxis Nosebleed

## Interventions

- **DRUG:** Tacrolimus capsule (low-dose)

## Key facts

- **NCT ID:** NCT04646356
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-10-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646356, "Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04646356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*